Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2020 | EHA 2020 CLL highlights: CLL14 & CAPTIVATE

Paolo Ghia • 22 Jun 2020
EHA 2020
Chronic Lymphocytic Leukemia Leukemia Antibodies Chlorambucil Ibrutinib Obinutuzumab Venetoclax
CAPTIVATE CLL14

Paolo Ghia, MD, of the Università Vita-Salute San Raffaele, Milan, Italy, explores highlights from EHA 2020, including the CLL14 trial (NCT02242942) investigating venetoclax-obinutuzumab in previously untreated, comorbid, chronic lymphocytic leukemia (CLL). The CAPTIVATE study (NCT02910583), which investigated measurable residual disease (MRD)-guided discontinuation and fixed duration therapy with the combination of ibrutinib and venetoclax is also discussed. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Paolo Ghia

Fixed-duration dose-reduced ibrutinib plus venetoclax: importance of toxicity reduction in CLL
1:11
Fixed-duration dose-reduced ibrutinib plus venetoclax: importance of toxicity reduction in CLL
Paolo Ghia • 11 Jun 2026
Is there promise for fixed-duration BTK and BCL2 inhibitor combination therapy in R/R CLL?
0:56
Is there promise for fixed-duration BTK and BCL2 inhibitor combination therapy in R/R CLL?
Paolo Ghia • 11 Jun 2026
Emerging third-generation BTK-targeted therapies for CLL: overcoming BTK resistance
1:22
Emerging third-generation BTK-targeted therapies for CLL: overcoming BTK resistance
Paolo Ghia • 11 Jun 2026
Dose-escalation results from the BELLWAVE-010 study of nemtabrutinib plus venetoclax in R/R CLL
1:29
Dose-escalation results from the BELLWAVE-010 study of nemtabrutinib plus venetoclax in R/R CLL
Paolo Ghia • 11 Jun 2026

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals